Identification of new epilepsy treatments: issues in preclinical methodology.
Epilepsia
; 53(3): 571-82, 2012 Mar.
Article
en En
| MEDLINE
| ID: mdl-22292566
ABSTRACT
Preclinical research has facilitated the discovery of valuable drugs for the symptomatic treatment of epilepsy. Yet, despite these therapies, seizures are not adequately controlled in a third of all affected individuals, and comorbidities still impose a major burden on quality of life. The introduction of multiple new therapies into clinical use over the past two decades has done little to change this. There is an urgent demand to address the unmet clinical needs for (1) new symptomatic antiseizure treatments for drug-resistant seizures with improved efficacy/tolerability profiles, (2) disease-modifying treatments that prevent or ameliorate the process of epileptogenesis, and (3) treatments for the common comorbidities that contribute to disability in people with epilepsy. New therapies also need to address the special needs of certain subpopulations, that is, age- or gender-specific treatments. Preclinical development in these treatment areas is complex due to heterogeneity in presentation and etiology, and may need to be formulated with a specific seizure, epilepsy syndrome, or comorbidity in mind. The aim of this report is to provide a framework that will help define future guidelines that improve and standardize the design, reporting, and validation of data across preclinical antiepilepsy therapy development studies targeting drug-resistant seizures, epileptogenesis, and comorbidities.
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Evaluación Preclínica de Medicamentos
/
Epilepsia
/
Investigación Biomédica Traslacional
/
Anticonvulsivantes
Tipo de estudio:
Diagnostic_studies
/
Guideline
/
Prognostic_studies
/
Systematic_reviews
Idioma:
En
Revista:
Epilepsia
Año:
2012
Tipo del documento:
Article
País de afiliación:
Estados Unidos